hrp0095p1-96 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Optimizing Diazoxide dose for the treatment of newborns with hyperinsulinemic hypoglycaemia (HH)

Neha Malhotra , Buddhi Gunasekara , Sapfo Athanasakopoulou , Clare Gilbert , Kate Morgan , Mehul Dattani , Antonia Dastamani

Introduction: Early initiation of diazoxide (DZX) treatment in neonates with HH can prevent permanent hypoglycaemic brain injury. The DZX standard therapeutic dose (STD) is 5 mg/kg/day, and rarely associated with adverse events. There are limited data for the effectiveness and safety of DZX low-dose (<5mg/kg/day) for the treatment of HH neonates.Aim: To assess efficacy and safety of low-dose DZX in HH newborns.<p ...

hrp0095lb1 | Late Breaking | ESPE2022

Amenorrhea in an Anorexia Nervosa patient as a presenting symptom of Cushing’s disease.

Avnon Ziv Carmit , T. Ben Harush Negari Shelly

Anorexia nervosa (AN) manifests in the restriction of energy intake relative to energy output. Atypical AN includes those who meet the criteria for AN but are not underweight. Hypothalamic amenorrhea can be a presenting symptom in AN, and the return of menses is part of recovery. It can take more than a year for menses to return after weight restoration and nutritional rehabilitation. Hypercortisolemia is common in AN, but usually does not cause cushingoid symptoms We describe...

hrp0095p2-2 | Adrenals and HPA Axis | ESPE2022

Retrospective cross-sectional study reviewing local practice in assessment of adrenal axis at a tertiary children’s hospital

Hester Holly , Hachemi Soraya , Amin Nadia , Alvi Sabah

Introduction: There is considerable variation in practice when assessing adrenal function in adrenal insufficiency; duration of glucocorticoid defined to confer risk, early morning cortisol assay (EMC), Synacthen test (ST) - both low dose (LDST) (1microgram) or standard dose (SDST) (36microgram/kg [maximum 250micrograms]) and symptomatology. At our tertiary children’s hospital, even between departments, there is variation in those identified as being at ...

hrp0095p2-80 | Diabetes and Insulin | ESPE2022

A MODY2 pedigree with GCK gene mutation and literatures review

Huang Siqi , Hou Lele , Meng Zhe , Liang Liyang

Objective: To report a family with MODY2 associated with GCK gene mutation and improve clinicians' understanding of this gene mutation.Methods: The clinical manifestations, laboratory examinations and genetic test results of a MODY2 family diagnosed and treated in our hospital were analyzed retrospectively, and the related literatures were reviewed.Results: The patient is a 6-...

hrp0092mte3 | Turner syndrome - Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International - Turner Syndrome Meeting | ESPE2019

New International Guidelines on Turner Syndrome

Gravholt Claus H.

Turner syndrome (TS) affects 25-50 per 100,000 females and can involve multiple organs through all stages of life, necessitating a multidisciplinary approach to care. Numerous important advances have been noted during recent years. These advances cover all specialty fields involved in the care of girls and women with TS. This new international guideline is based on an international effort with emphasis on 1) diagnostic and genetic issues, 2) growth and development during child...

hrp0092rfc11.6 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

Final Height Reduction in Transgender Adolescent Girls: A Case Series

Hellinga Ilse , Wiepjes Chantal , Vink Denise , Rotteveel Joost , Klink Daniel

Background: Transgirls (female-identifying adolescents assigned male at birth) can be treated with GnRH (gonadotropin releasing hormone analogs) followed by the addition of estrogens.Recently in a small cohort of 25 transgirls their average final height was reported to be +1.9 SDS (standard deviation score) calculated for adult Dutch females.High dosage estrogens can be used to stimulate bone maturation, thereb...

hrp0092p1-70 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

Congenital Hypothyroidism – Precise Diagnosis with Dual Imaging

Kasongo Laura , Rausin Leon , Nicolescu Ramona

Introduction: Primary congenital hypothyroidism (PCH), defined as thyroid hormone deficiency, can be viewed as an anatomical, clinical, biochemical and radiological spectrum.Its etiology includes thyroid dysgenesis (85%) with defects in thyroid gland development and thyroid dyshormonogenesis (15%) with inborn error of thyroxine synthesis or release.There is growing evidence that precise characterization of ...

hrp0092p1-161 | Adrenals and HPA Axis (1) | ESPE2019

Perioperative Control of Blood Pressure in a Child with Paraganglioma Using Esmolol

Babiker Amir , Al Hamdan Wejdan , Habeb Abdulhadi , Alfakeeh Khalid , Al Namshan Mohammed , AlHerbi Talal , Al Dubayee Mohammed , Al Juraibah Fahad , Attasi Abdul Aleem

Background: Paragnagliomas and pheochromocytomas are rare neuroendocrine tumors that originate from the paraganglionic cells of the autonomic nervous systems. These tumors may be extra or intra-adrenal in site. The use of antihypertensive medications is usually challenging in these patients. Long acting alpha and beta blockade can be quite useful preoperatively but challenging postoperatively. We present a case of familial paraganglioma that was successfully t...

hrp0092p2-76 | Diabetes and Insulin | ESPE2019

Coexistence of Medium chain acyl-CoA dehydrogenase deficiency (MCADD) and Type 1 diabetes (T1D): A management challenge

Afreh-Mensah Donald , Agwu Juliana C.

Background: Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive fatty acid β-oxidation defect. The enzyme is important in the breakdown of medium chain fats into acetyl-CoA to produce ketones, alternative energy source when glucose hepatic glycogen stores become depleted during prolonged fasting. In MCADD, during periods of fasting/ acute illness, there are insufficient ketones to compensate for the glucose energy deficit, ...

hrp0092p3-18 | Adrenals and HPA Axis | ESPE2019

The Unusual Adverse Side Effects of Super-Potent Topical Steroids

Abdelmeguid Yasmine , Mahfouz Shaymaa

Background: Topical steroids are commonly used in clinical practice for management of dermatological diseases. Clobetasol propionate is the most potent. They are systemically absorbed and may cause adverse side effects due to improper and prolonged use, such as iatrogenic Cushing's syndrome and adrenal insufficiency due to suppression of hypothalamic-pituitary-adrenal axis.Case presentation: A 7-month-old boy referre...